Literature DB >> 8683964

Personality disorders according to DSM-III-R and thrombocyte monoamine oxidase activity in type 1 and type 2 alcoholics.

J Hallman1, L von Knorring, L Oreland.   

Abstract

OBJECTIVE: Several criteria used to distinguish type 2 alcoholics from Type 1 alcoholics, as well as the incidence of lower platelet monoamine oxidase (MAO) activity in the former group, would indicate that personality disorders might be more common in Type 2 alcoholics. The purpose of the present study was to investigate the relation between personality disorders, according to DSM-III-R, platelet MAO activity and Type 1/Type 2 alcoholism.
METHOD: The occurrence of personality disorders, according to DSM-III-R, was studied in a series of 34 male inpatients with alcohol dependence, subclassified into Type 1 (n = 18) and Type 2 (n = 16). Platelet MAO activity was studied in the same series of patients.
RESULTS: Patients with Type 2 alcoholism had significantly higher frequencies of self-defeating, schizotypal, antisocial and borderline personality disorders than Type 1 alcoholics. Patients with Type 2 alcoholism had significantly lower mean activity of platelet MAO than Type 1 alcoholics. No correlation was found between platelet MAO activity and personality disorders according to DSM-III-R.
CONCLUSIONS: Disorders of the antisocial personality and borderline personality types as well as low platelet MAO can all predict the occurrence of Type 2 alcoholism with rather high specificity but with a comparatively low degree of sensitivity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683964     DOI: 10.15288/jsa.1996.57.155

Source DB:  PubMed          Journal:  J Stud Alcohol        ISSN: 0096-882X


  2 in total

1.  Parental alcohol use and brain volumes in early- and late-onset alcoholics.

Authors:  Jodi M Gilman; James M Bjork; Daniel W Hommer
Journal:  Biol Psychiatry       Date:  2007-02-16       Impact factor: 13.382

2.  Association of personality disorders with Type A and Type B alcoholics.

Authors:  Miriam Bottlender; Ulrich W Preuss; Michael Soyka
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-27       Impact factor: 5.270

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.